Occurence of a novel t(11;19)(q13;q13.3) in complete remission of acute promyelocytic leukemia

Temperani, Paola; Luppi, Mario; Giacobbi, Francesca; Vaccari, Paola; Longo, Giuseppe; Donelli, Amedea; Narni, Franco; Torelli, Giuseppe; Emilia, Giovanni

doi:10.1016/s0165-4608(97)00223-9

Cited by 4 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, our subset of patients is the largest group to be described where secondary CCA are being detected after treatment for APL, without concurrent development of secondary MDS/AML. MDS occurring after successful therapy for APL is rare but well-documented [3][4][5][6][7][8][9][10][11][12]. Two of the larger studies published previously, reported incidences of 0.97% and 6.5% [5,6].…”

Section: Discussionmentioning

confidence: 99%

“…Acute promyelocytic leukemia (APL) is a highly curable disease with high complete remission (CR) and long-term survival rates [1,2]. Secondary clonal chromosomal aberrations (CCA) associated with the development of secondary myelodysplastic syndrome (MDS) are being reported with increasing frequency in patients successfully treated for APL [3][4][5][6][7][8][9][10][11][12][13]. Patients are typically in hematological and cytogenetic remission for APL; however, at cytogenetic follow-up post treatment, have CCA detected, without evidence of the original t(15;17)(q22;q21) seen at APL diagnosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia

Batzios

Hayes

et al. 2009

American J Hematol

View full text Add to dashboard Cite

To identify patients who developed secondary clonal cytogenetic aberrations (CCA) following therapy for acute promyelocytic leukemia (APL), we retrospectively analyzed cytogenetic results from 123 patients diagnosed with APL between 1995 and 2007, who had ongoing cytogenetic analysis undertaken in our laboratory. During follow-up for APL we identified 12 patients (9.8%) who developed CCA, not detected at diagnosis of APL and unrelated to their original APL karyotype. All patients had received all-trans retinoic acid (ATRA) and chemotherapy and were in complete remission for APL when secondary CCA were identified. The median latency period between diagnosis of APL and emergence of secondary CCA was 27.5 months (range: 2-54 months). To date, four patients with CCA have been diagnosed with therapy-related myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (t-AML), giving a median t-MDS/AML free survival of 78 months, with follow-up ranging between 20 and 136 months from APL diagnosis. Three patients have died: two patients died of t-AML and another developed relapsed APL with persistence of his secondary clone but no diagnosis of t-MDS/AML and died from transplant-related complications. Two patients are alive with t-MDS. Seven patients with CCA are alive with no morphological evidence of MDS at the time of their last known follow-up; thus median survival has not been reached. The appearance of these abnormalities in the absence of morphological evidence of MDS in the majority of patients is unusual, and highlights the importance of continued cytogenetic follow-up in these patients. Am. J. Hematol., 2009. (c) 2009 Wiley-Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia

Batzios

Hayes

et al. 2009

American J Hematol

View full text Add to dashboard Cite

show abstract

“…t(11;19) has been reported as a rare recurrent secondary change in AML (Sato et al, 1995;Giles et al, 1997). Of interest is the report by Temperani et al (1998), who described an APL patient treated with TIs who developed an asymptomatic, small clone of cells with t(11;19) as the sole abnormality.…”

Section: Other Subset Of Rare Abnormalitiesmentioning

confidence: 99%

Rare recurring balanced chromosome abnormalities in therapy‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop†

Block

Carroll

Hagemeijer³

et al. 2002

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Seventy-seven patients were identified with Rare recurring (excluding 11q23, 21q22, inv(16), and t(15;17)) chromosome abnormalities among 511 patients with treatment-related myelodysplastic syndromes and acute leukemia accepted from centers in the United States, Europe, and Japan. The abnormality subsets included 3q21q26 (17 patients), 11p15 (17 patients), t(9;22)(q34;q11) (10 patients), 12p13 (9 patients), t(8;16)(p11;p13) (9 patients), and an "other" subset, which included t(6;9)(p23;q34) (3 patients), t(10;11)(p13;q13 approximately q21) (3 patients), t(1;17)(p36;q21) (2 patients), t(8;14)(q24;q32) (2 patients), t(11;19)(q13;q13) (2 patients), t(1;3)(p36;q21) (2 patients), and t(3;5)(q21;q31) (1 patient). Increased karyotypic complexity with additional balanced and unbalanced rearrangements was observed in 70% of cases. Among 54 cases with secondary abnormalities, chromosome 5 and/or 7 abnormalities were observed in 59%. The most frequent primary diseases were breast cancer (24 cases), Hodgkin disease (14 cases), non-Hodgkin lymphoma (10 cases), and de novo ALL (5 cases). Thirty-seven patients received alkylating agents plus topoisomerase II inhibitors with or without radiation therapy. The presenting diagnosis was t-AML in 47 cases, t-MDS in 23 cases (10 progressed to t-AML), and t-ALL in seven cases, five of whom had a t(9;22). The median latency time from initiation of original therapy to therapy-related disease diagnosis was quite long (69 months), and the overall median survival from the date of therapy-related disease diagnosis was very short (7 months). The 1-year survival rate was 34 +/- 7%, with no significant differences among subsets. Comparison with previously reported cases showed increased karyotypic complexity and adult presentation of pediatric-associated chromosome abnormalities.

show abstract

“…We describe two patients who developed distinct AML clones without t(15;17) following treatment for APL. Such secondary clonal hematologic neoplasia occurring after successful therapy for APL is rare but has been documented, and these cases are illustrated in Table 1 [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] . Frequencies ranging from 1–9.8% [18] , [20] , [29] , [33] have been reported with a median latency period of 35.6 months (range 1–158 months) after remission of APL.…”

Section: Discussionmentioning

confidence: 99%

Secondary clonal hematologic neoplasia following successful therapy for acute promyelocytic leukemia (APL): A report of two cases and review of the literature

Gaut

Sasine

Schiller

2018

Leukemia Research Reports

View full text Add to dashboard Cite

Although rare, secondary clonal hematologic neoplasia may occur after successful therapy for acute promyelocytic leukemia (APL). These secondary clonal events may be considered therapy-related, but may also be due to an underlying background of clonal hematopoiesis from which both malignancies may develop. In this manuscript, we describe two patients with secondary clones after APL therapy characterized in one patient by deletion of chromosome 11q23 and, in the other, by monosomy of chromosome 7, and also provide a review of all secondary clonal disorders described after APL therapy. We suggest that since most reports identify karyotypic abnormalities not typically associated with chemotherapy, there may be another mechanism underlying secondary clonal development after complete response to initial APL therapy.

show abstract

Occurence of a novel t(11;19)(q13;q13.3) in complete remission of acute promyelocytic leukemia

Cited by 4 publications

References 7 publications

Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia

Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia

Rare recurring balanced chromosome abnormalities in therapy‐related myelodysplastic syndromes and acute leukemia: Report from an International Workshop†

Secondary clonal hematologic neoplasia following successful therapy for acute promyelocytic leukemia (APL): A report of two cases and review of the literature

Contact Info

Product

Resources

About